- Home
- TWFG vs THRD Comparison
TWFG vs THRD Comparison
Compare TWFG & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- THRD
- Stock Information
- Founded
- TWFG 2001
- THRD 2019
- Country
- TWFG United States
- THRD United States
- Employees
- TWFG N/A
- THRD N/A
- Industry
- TWFG
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- TWFG
- THRD Health Care
- Exchange
- TWFG NYSE
- THRD Nasdaq
- Market Cap
- TWFG 484.1M
- THRD 513.2M
- IPO Year
- TWFG 2024
- THRD 2022
- Fundamental
- Price
- TWFG $29.23
- THRD $10.84
- Analyst Decision
- TWFG Buy
- THRD Strong Buy
- Analyst Count
- TWFG 8
- THRD 3
- Target Price
- TWFG $31.14
- THRD $20.33
- AVG Volume (30 Days)
- TWFG 175.4K
- THRD 259.3K
- Earning Date
- TWFG 02-15-2025
- THRD 11-07-2024
- Dividend Yield
- TWFG N/A
- THRD N/A
- EPS Growth
- TWFG N/A
- THRD N/A
- EPS
- TWFG 0.43
- THRD N/A
- Revenue
- TWFG $194,211,000.00
- THRD N/A
- Revenue This Year
- TWFG $19.28
- THRD N/A
- Revenue Next Year
- TWFG $19.53
- THRD N/A
- P/E Ratio
- TWFG $67.98
- THRD N/A
- Revenue Growth
- TWFG 26.18
- THRD N/A
- 52 Week Low
- TWFG $21.31
- THRD $8.08
- 52 Week High
- TWFG $36.50
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- THRD 40.49
- Support Level
- TWFG N/A
- THRD $10.53
- Resistance Level
- TWFG N/A
- THRD $11.84
- Average True Range (ATR)
- TWFG 0.00
- THRD 0.86
- MACD
- TWFG 0.00
- THRD -0.07
- Stochastic Oscillator
- TWFG 0.00
- THRD 17.60
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.